Fair Value Measurements (Tables)

9 Months Ended

Sep. 30, 2015

	September 30,		Quoted Prices in Active Markets		Significant Other Observable Inputs		Unobservable Inputs
Description	2015		(Level 1)		(Level 2)		(Level 3)
Assets:
Cash and cash equivalents	$	12,413	$	12,413	$	-	$	-
Total assets	$	12,413	$	12,413	$	-	$	-

Liabilities:
Warrants potentially settleable in cash	$	3,096	$	-	$	-	$	3,096
Total liabilities	$	3,096	$	-	$	-	$	3,096

	December 31,		Quoted Prices in Active Markets		Significant Other Observable Inputs		Unobservable Inputs
Description	2014		(Level 1)		(Level 2)		(Level 3)
Assets:
Cash and cash equivalents	$	3,970	$	3,970	$	-	$	-
Marketable securities		1,975		-		1,975		-
Total assets	$	5,945	$	3,970	$	1,975	$	-

Liabilities:
Warrants potentially settleable in cash	$	8,464	$	-	$	-	$	8,464
Total liabilities	$	8,464	$	-	$	-	$	8,464

	Fair Value Measurements Using Significant Unobservable Inputs (Level 3)
	September 30, 2015			September 30, 2014
Balance , January 1,	$	8,464		$	23
Change in fair value of Teva option		-			(23	)
Estimated fair value of warrants assumed in merger on January 2, 2014		-			10,475
Estimated fair value of warrants issued in January 2014 common stock sale		-			3,696
Estimated fair value of warrants exchanged for common shares		(13,862	)		-
Change in fair value of warrants		8,494			(6,929	)
Balance at September 30, 2015 and 2014	$	3,096		$	7,242